Penile metastasis from carcinoma of the prostate in a patient with high serum prostate specific antigen levels
Sciarra, A.; D'Eramo, G.; Casale, P.; Di Nicola, S.; Di Chiro, C.; De Santis, C.; Loreto, A.; Di Silverio, F.
Minerva Urologica e Nefrologica 51(3): 157-158
1999
ISSN/ISBN: 0393-2249 PMID: 10638179 Document Number: 498919
Prostatic carcinoma metastasizing to the penis is rare. Prognosis is poor with survival ranging from 1 to 24 months. A patient with prostate cancer and a serum Prostate Specific Antigen (PSA) level over 200 ng/ml, submitted to radical retropubic prostatectomy (RRP) and after 2 months presenting with two painful nodules in the penis, is described.
Document emailed within 1 workday
Related Documents
Amayo, A.; Obara, W. 2004: Serum prostate specific antigen levels in men with benign prostatic hyperplasia and cancer of prostate East African Medical Journal 81(1): 22-26Romppanen, J.; Haapalainen, T.; Punnonen, K.; Penttilä, I. 2002: Serum sialic acid and prostate-specific antigen in differential diagnosis of benign prostate hyperplasia and prostate cancer Anticancer Research 22(1a): 415-420
Wu, C.T.; Chuang, C.K.; Chou, C.C.; Chu, S.H.; Chen, H.W.; Chen, C.S.; Chiang, Y.J.; Liao, S.K. 2000: The role of free to total prostate-specific antigen ratio for prostate cancer in screening patients with total serum levels between 4 and 20 ng/ml Chang Gung Medical Journal 23(3): 142-148
Stenman, U.H.; Leinonen, J.; Alfthan, H.; Rannikko, S.; Tuhkanen, K.; Alfthan, O. 1991: A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer Cancer Research 51(1): 222-226
Miyamoto, S.; Jimbo, H.; Totsuka, Y.; Mashimo, T.; Umeyama, T.; Uehara, H.; Shinozaki, T. 1995: Change in serum prostate specific antigen values in men who had no evidence of prostate cancer on initial biopsy Hinyokika Kiyo. Acta Urologica Japonica 41(10): 767-770
Obralic, N.; Kulovac, B.; Aganovic, D.; Junuzovic, D. 2009: Values of prostate specific antigen in patients with operable prostate carcinoma Medicinski Arhiv 63(1): 34-37
Semjonow, A.; Hertle, L. 1995: Can the tumor stage of prostate carcinoma be determined with the aid of prostate-specific antigen? Der Urologe. Ausg. a 34(4): 290-296
Bentvelsen, F.M.; Bogdanowicz, J.F.; Oosterom, R.; Schröder, F.H. 1990: A comparison between prostate-acid-phosphatase and prostate-specific antigen in the diagnosis of prostatic carcinoma Nederlands Tijdschrift Voor Geneeskunde 134(33): 1596-1600
Vaidya, H.C.; Wolf, B.A.; Garrett, N.; Catalona, W.J.; Clayman, R.V.; Nahm, M.H. 1988: Extremely high values of prostate-specific antigen in patients with adenocarcinoma of the prostate; demonstration of the "hook effect" Clinical Chemistry 34(10): 2175-2177
Cerović, S.; Dimitrijević, J.; Milović, N.; Ajdinović, B.; Knezević-Usaj, S.; Popović, L.; Brajusković, G. 2002: Prostate-specific antigen in the diagnosis and treatment of carcinoma of the prostate Vojnosanitetski Pregled 59(6 Suppl): 53-57
Mannini, D.; Aiello, E.; Maver, P.; Corrado, G.; Vecchi, F.; Bellanova, B. 1987: Simultaneous determination of prostatic acid phosphatase and prostate-specific antigen in carcinoma of the prostate. 2 years' experience Minerva Urologica e Nefrologica 39(4): 335-341
Yamaguchi, K.; Tanaka, M.; Kitagawa, N.; Kotake, T.; Yanagi, S.; Ito, H. 1989: The significance of serum prostate-specific antigen, gamma-seminoprotein and prostatic acid phosphatase as prostate cancer markers Hinyokika Kiyo. Acta Urologica Japonica 35(6): 987-991
Xu, Z.-Q.; Hua, L.-X.; Qian, L.-X.; Wu, H.-F. 2002: Effect of transrectal prostatic biopsy on serum prostate specific antigen levels Zhonghua Nan Ke Xue 8(5): 341-342
Martin, A.A.; Clejan, S. 1994: Prostate specific antigen density: a method for differentiating prostate carcinoma from benign prostatic hypertrophy demonstrates ethnic variation Journal of the Louisiana State Medical Society: Official Organ of the Louisiana State Medical Society 146(4): 163-171
Rahardjo, D.; Kamil, S.T.; Pakasi, L.S. 2000: Rationale for using serum prostate-specific antigen (PSA) level and PSA density (PSAD) to detect prostatic malignancy in a country with low prostate cancer incidence Gan to Kagaku Ryoho. Cancer and ChemoTherapy 27(Suppl 2): 563-570
Gupta, A.; Gupta, D.; Raizada, A.; Gupta, N.Prasad.; Yadav, R.; Vinayak, K.; Tewari, V. 2014: A hospital based study on reference range of serum prostate specific antigen levels Indian Journal of Medical Research 140(4): 507-512
Schmid, H.P. 1998: Prostate carcinoma: prostate-specific antigen--and then what? Therapeutische Umschau. Revue Therapeutique 55(7): 426-428
Boroumand, M.A.; Anvari, M.S.; Amelimojarad, E.; Shoar, S.; Naderan, M.; Yazdanifard, P.; Karimi, A.; Goodarzynejad, H. 2011: Association Between Angiographically Assessed Coronary Artery Disease and Serum Levels of Prostate Specific Antigen Clinical Laboratory 57(11-12): 975-981
Nixon, R.G.; Lilly, J.D.; Liedtke, R.J.; Batjer, J.D. 1997: Variation of free and total prostate-specific antigen levels: the effect on the percent free/total prostate-specific antigen Archives of Pathology and Laboratory Medicine 121(4): 385-391
Stromberg, J.S.; Martinez, A.A.; Horwitz, E.M.; Gustafson, G.S.; Gonzalez, J.A.; Spencer, W.F.; Brabbins, D.S.; Dmuchowski, C.F.; Hollander, J.B.; Vicini, F.A. 1997: Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer: superior prostate-specific antigen response compared with external beam treatment Cancer Journal from Scientific American 3(6): 346-352